Thymosin Alpha 1 is a peptide, that is naturally produced by the thymus gland with antibacterial and antifungal properties, that plays an important role in immune modulation and response. Thymosin Alpha 1 peptide injection therapy can be prescribed to help strengthen the immune system; fight chronic viral diseases and autoimmune processes; increase vaccine effectiveness; suppress infection and tumor growth; and help control inflammation associated with chronic diseases.

Benefits of Thymosin Alpha 1

• STRENGTHEN IMMUNE SYSTEM - Thymosin Alpha 1 helps modulate the immune system by augmenting T-cell function.

• FIGHT AUTOIMMUNE & VIRAL DISEASES - Thymosin Alpha 1 can help improve symptoms associated with autoimmune and viral diseases including chronic fatigue, Lyme disease, hepitits B and C, malignant melanoma, hepatocellular carcinoma, drug-resistant tuberculosis, Di George’s syndrome as well as any chronic cancer or viral disease. 

• CONTROL INFLAMMATION - Thymosin Alpha 1 helps control inflammation associated with chronic diseases, which can cause excess fatigue.

About Thymosin Alpha 1

Thymosin Alpha 1 is a polypeptide hormone secreted by the thymus, which is a vital component of the immune system that controls the maturation of T-cells.

T-cells have a number of variants that perform different roles within immune system regulation, including helper, killer, regulatory, and others.  Killer T-cells destroy cells which are cancerous or infected with bacteria or viruses, while helper T-cells help coordinate the attack.

Thymosin Alpha A helps modulate the immune system by augmenting T-cell function. 

It is most often given for chronic viral diseases, but has also been shown to increase innate immunity factors and help fight against harmful autoimmune processes. It is given to help control inflammation associated with chronic diseases, which can cause excess fatigue.

Thymosin Alpha 1 is marketed worldwide as Zadaxin™ (thymalfasin, SciClone Pharmaceuticals, China). It has been used to support immunity in over 3,000 patients and in over 70 clinical studies, either as monotherapy or in conjunction with current allopathic medicines. Zadaxin is currently in Phase III trials for the treatment of hepatitis C and in Phase II trials for hepatitis B in the United States. The lack of significant side effects with thymosin alpha 1 is in sharp contrast to other major immune response modulators such as IFN and IL-2, which can lead to flu-like symptoms including malaise, fever, headache, chills and pulmonary edema (with IL-2).

*This product is not FDA approved and therefore outside of clinical use, but substantial information is available on its role in clinical observational trials.